Coherus Biosciences | CHRS


Peers Price Chg Day Year Date
Fujifilm 3,607.00 40.00 1.12% -4.60% Sep/05
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Amarin 15.33 0.30 2.00% 27.64% Sep/05
Baxter International 24.42 0.84 3.56% -37.34% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Ironwood Pharmaceuticals 1.16 0.06 5.45% -74.28% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Myriad Genetics 6.61 -0.18 -2.65% -75.49% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Perrigo 23.49 -0.25 -1.05% -19.14% Sep/02
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Teva Pharmaceutical Industries 6,362.00 87.00 1.39% -5.45% Sep/07
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05
Xencor 8.55 0.18 2.15% -47.16% Sep/05
Zoetis 153.32 0.12 0.08% -19.13% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US400 3297 16.31 0.50% 12.16% Sep/05

Coherus Biosciences traded at $2.47 this Tuesday April 9th, decreasing $0.04 or 1.59 percent since the previous trading session. Looking back, over the last four weeks, Coherus Biosciences lost 8.81 percent. Over the last 12 months, its price fell by 68.49 percent. Looking ahead, we forecast Coherus Biosciences to be priced at 2.45 by the end of this quarter and at 2.39 in one year, according to Trading Economics global macro models projections and analysts expectations.

Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.